The Michael J. Fox Foundation for Parkinson's Research
Church Street Station
PO Box 780
New York
NY
10008
Tel: 212509-0995
73 articles with The Michael J. Fox Foundation for Parkinson's Research
-
Michael J. Fox Foundation for Parkinson's Research and Parkinson Alliance Announce Transition of the Parkinson's Unity Walk
9/8/2022
The Michael J. Fox Foundation for Parkinson's Research and The Parkinson Alliance announced that the Parkinson's Unity Walk — a fundraising event held each April in New York City's Central Park — will be hosted by MJFF starting in 2023.
-
Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
8/24/2022
Seelos Therapeutics, Inc. today announced it was selected to receive a grant from The Michael J. Fox Foundation for Parkinson's Research to advance preclinical research and development of its gene therapy delivered SLS-004 program.
-
Koneksa Awarded a Grant from The Michael J. Fox Foundation to Evaluate Disease Progression Using Digital Measures in Parkinson’s Disease
8/8/2022
Koneksa , a healthcare technology company pioneering digital biomarkers, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant to evaluate Parkinson’s disease (PD) progression using digital measures.
-
Koneksa and Northwestern University Awarded a Grant from The Michael J. Fox Foundation to Investigate Speech Symptoms in Parkinson’s Disease
6/16/2022
Koneksa , a healthcare technology company pioneering digital biomarkers, announced today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in collaboration with Northwestern University.
-
Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson’s Research to Support Development of Its TLR2 Program
4/19/2022
Neuropore Therapies, Inc. announced that it received a $4.8M grant from The Michael J. Fox Foundation for Parkinson’s Research.
-
Lucy Therapeutics Receives $4.9 Million Grant from Michael J. Fox Foundation
4/11/2022
Funding will help LucyTx unlock the secrets of mitochondria to develop novel drugs to treat Parkinson’s disease Lucy Therapeutics, a biotech with a unifying mitochondrial platform, announced it secured funding from The Michael J. Fox Foundation for Parkinson’s Research, the largest nonprofit funder of Parkinson's disease research.
-
Caraway Therapeutics Receives Third Research Grant from The Michael J. Fox Foundation to Continue Advancement of TRPML1 Agonists for GBA-Parkinson’s Disease
1/26/2022
Caraway Therapeutics today announced that the Company has been awarded a third research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
-
The Michael J. Fox Foundation Launches the Bachmann-Strauss Fellowship in Dystonia Research
1/18/2022
The Michael J. Fox Foundation for Parkinson's Research announces a new training program to grow the global base of researchers studying the movement disorder dystonia.
-
Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Support UB-312 Vaccine Study
1/10/2022
Vaxxinity, Inc. has announced that the company has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research for the exploration of markers for target engagement in individuals with Parkinson’s disease.
-
Cantabio Pharmaceuticals Awarded Grant From The Michael J. Fox Foundation to Develop Novel Small-Molecule Aggregation Inhibitors of the Tau Protein for the Treatment of Parkinson’s Disease
1/5/2022
Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson's Research has awarded the Company a major grant for a project entitled "Development of small-molecule inhibitors to reduce the aggregation of tau for the treatment of Parkinson's disease."
-
Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease
1/4/2022
Cognition Therapeutics, Inc. today announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
-
Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.
-
The Michael J. Fox Foundation Launches New Guide to Provide Insights and Practical Strategies for Spanish-Speaking Patients and Families on Navigating the Parkinson's Journey
9/17/2021
Newly translated resource in Spanish offers informative, candid first-hand reflections and practical strategies on understanding and living with Parkinson's disease
-
California Funds Parkinson's Disease Registry with Advocacy and Support from The Michael J. Fox Foundation
7/14/2021
The Michael J. Fox Foundation for Parkinson's Research (MJFF) today commended California Governor Gavin Newsom for signing the state's FY 2021-2022 budget that includes $8.4 million to fund the California Parkinson's Disease Registry (CPDR) and to expand it to other neurodegenerative diseases over the next four years.
-
The Michael J. Fox Foundation Releases New Guide, Deep Brain Stimulation and Parkinson's
6/15/2021
With an estimated 6 million people worldwide living with Parkinson's, and an estimated 60,000 newly diagnosed annually, resources to help navigate available treatments to manage Parkinson's care are critical.
-
Michael J. Fox Foundation and 23andMe Share New Genetic Data from the Largest Cohort in Parkinson's Research
6/8/2021
Collaboration with 23andMe enables robust sharing of de-identified genetic data with researchers worldwide through the Fox Insight Data Exploration Network (Fox DEN)
-
The Michael J. Fox Foundation for Parkinson's Research Adds Melanie Bolch Isbill, Alex Krys and Jack Quinn to Its Board of Directors
4/20/2021
The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced that during its Board meeting on March 11, 2021 , three new members were appointed to the Board of Directors — Melanie Bolch Isbill , Alex Krys and Jack Quinn.
-
Clene Nanomedicine Awarded Michael J. Fox Foundation Grant to Accelerate the Development of CNM-Au8 as a Treatment for Parkinson’s Disease
3/1/2021
Interim data from a Phase 2 target engagement study show that CNM-Au8 treatment was associated with improvements across key CNS bioenergetic metabolites in Parkinson’s disease patients
-
Yesse Technologies secures another grant from The Michael J. Fox Foundation to sniff out Parkinson's disease
1/19/2021
Yesse Technologies, Inc., a New York-headquartered biotechnology company, developing a technology platform to digitize the sense of smell, announces that it was awarded a $670,000 grant from The Michael J. Fox Foundation for Parkinson's Research.
-
Sengenics Awarded Prestigious Michael J. Fox Foundation Grant to Determine the Role of Autoantibodies in the Progression of Parkinson’s
12/15/2020
Sengenics, the Functional Proteomics Company, has been awarded a prestigious research grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to identify novel autoantibody signatures related to non-motor symptoms in individuals with high risk of Parkinson’s disease (PD) from the Parkinson’s Associated Risk Study (PARS). The objective of the study will be to leverage KREX-based Immunome protein arrays to identify a